Form SC 13D/A NEVRO CORP Filed by: Engaged Capital LLC

Go back to Form SC 13D/A NEVRO CORP Filed by: Engaged Capital LLC

Oppenheimer Downgrades Nevro Corp (NVRO) to Perform, 'unclear path to material growth'

February 22, 2024 6:51 AM EST

Oppenheimer analyst Suraj Kalia downgraded Nevro Corp (NYSE: NVRO) from Outperform to Perform.

The analyst comments "4Q23 revs in line with pre-release ($116M). PDN contribution of $22.4M (+29% y/y, ~+8% seq.). Continued weakness in core SCS (-3% y/y). Ex-PDN, core US SCS... More